Pulmonx Corporation LUNG Proceeds from repayments of a nonrecourse promissory note
Proceeds from repayments of a nonrecourse promissory note at other companies
Other financials
Where this comes from
Reported directly by Pulmonx Corporation in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock.
The official record: Pulmonx Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pulmonx Corporation's proceeds from repayments of a nonrecourse promissory note.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pulmonx Corporation's proceeds from repayments of a nonrecourse promissory note?
- Pulmonx Corporation (LUNG) reported proceeds from repayments of a nonrecourse promissory note of $201K in Q1 2026.
- How has Pulmonx Corporation's proceeds from repayments of a nonrecourse promissory note changed year-over-year?
- Pulmonx Corporation's proceeds from repayments of a nonrecourse promissory note decreased by 63.7% year-over-year, from $554K to $201K.
- What does proceeds from repayments of a nonrecourse promissory note mean?
- This represents cash inflows received by the company resulting from the repayment of loans or notes receivable that were previously extended to third parties, often related to asset purchases or strategic financing arrangements. It reflects the recovery of capital deployed in financing activities rather than core operational revenue. Investors analyze this to understand the company's role as a creditor and the timing of cash inflows from non-operating lending activities.